Marni Falk, the director of the Mitochondrial-Genetic Disease Clinic at The Children's Hospital of Philadelphia, is preparing a pilot human study to test a promising theory for treating mitochondrial diseases.
A team of investigators at the Florida branch of Scripps Research Institute says that a little-understood enzyme known as serum glucocorticoid kinase 1 could play a role in preventing or treating Parkinson's disease.
Melanoma can find a safe haven from the BRAF inhibitors designed to stop the cancer. And a group of scientists at the Frick Institute say they have some ideas on shutting that haven down.
MIT's Dane Wittrup, one of the scientific founders behind Eleven Biotherapeutics, says he and a trio of grad students have developed some significant new insights into amping up the performance of cancer immunotherapies.
Armed with NIH funding, a group of investigators at the University of Chicago Medical Center have been studying the positive effects of an ancient Chinese remedy derived from magnolia tree bark, which may have potential in guarding against heart disease.
A group of investigators at the University of Zurich say that they have identified a key signaling pathway for B cell lymphoma, adding that experimental drugs now in the clinic are already designed to target it.
An investigator at Columbia University Medical Center with close ties to Tarrytown, NY-based Armgo Pharma has published new animal data to back up the promise of their clinical-stage diabetes drug Rycal.
Shares of Regulus spiked 10% Tuesday afternoon after its Big Pharma partner AstraZeneca stepped up to grab rights to a preclinical drug candidate for NASH with plans to steer it into clinical studies.
Investigators at the Whitehead Institute have adapted promising new CRISPR-Cas9 gene editing technology to go to work finding new therapeutic approaches to fighting fungal infections.
Working on a new initiative to move drugs out of discovery and into the clinic, Sanford-Burnham Medical Research Institute has struck a deal with Daiichi Sankyo to advance a new cardio drug into human studies.
A pair of research teams at UC Berkeley and Harvard has come up with some new avenues of research that hold the promise of finding new drugs to treat cachexia, the deadly wasting disease that afflicts cancer patients.
Google's Calico has been looking for a mix of clinical-stage development programs and promising scientific exploration that can be translated into new therapies. Today it pulled back the wraps from a partnership it formed with UC San Francisco's acclaimed Peter Walter, whose lab has been working on the ways cells function while under stress.
Alcoholics face a laundry list of potential health problems, including an increased risk of skin infections due to a compromised immune response. Now a team of investigators has highlighted the well-known link between alcoholism and skin infections, while pointing to a therapeutic target that could reduce or eliminate the risk of infection.
The European Respiratory Society and American Thoracic Society have joined forces to highlight what we don't know about COPD in order to steer future research programs in the right way.
It turns out that mice are much better equipped than humans when it comes to regenerating and repairing the liver. A group of investigators at UC Davis note that the main difference is that rodents can rely on mouse PPARα that is much more efficient than human PPARα. And they've tested another protein, fibroblast growth factor 21, that could make up the difference for humans.
AstraZeneca's AZD0530 proved a disappointment as a new drug for solid tumors, but a Yale team says it may prove more effective in a new program for Alzheimer's.
A pair of researchers at the University of Michigan Comprehensive Cancer Center say they have been making fresh progress on a new therapeutic approach to a relatively rare form of acute leukemia. And the biotech that in-licensed the work heralded the latest advance as another indication of the promise it holds for the cancer field.
A year after Concert Pharmaceuticals translated its work using deuterium to amp up the efficacy and stability of drugs into an upsized $84 million IPO, the biotech says it's completed a positive animal study on a new treatment designed to prevent seizures.
In the world of Alzheimer's drug research, there's no lack of certainty among leading researchers. There's just no consensus on what causes the disease or how to treat it.